[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Kolding Sygehus\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,64,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100565455","monitoring-lupus-nephritis-through-urinary-extracellular-vesicles-100565455",false,"NCT06642402","Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles","Monitoring and Detecting Lupus Nephritis Through Urinary Extracellular Vesicles in Urine","SLE patients with kidney involvement\n\nInclusion criteria:\n\n* \\> 18 years old\n* Fulfilling the 2019 EULAR\u002FACR classification criteria\n* Positive autoantibodies, medical history and obejctive examination compatible with SLE\n* Referred to kidney biopsy\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nSLE patients with no sign of kidney disease\n\nInclusion criteria:\n\n* \\> 18 years old\n* Fulfilling the 2019 EULAR\u002FACR classification criteria\n* Positive autoantibodies, medical history and obejctive examination compatible with SLE\n* Normal plasma creatinine\n* Urine albumine\u002Fcreatinine \\\u003C 100 mg\u002Fg\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nHealthy controls:\n\nInclusion criteria:\n\n* \\> 18 years old\n* No known kidney disease\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Urine albumin-creatinine ratio \\> 100 mg\u002Fg or proteinuria \\> 100 mg\u002Fday\n* Postive autoantibodies\n* Significant comorbidity, which is considered to potentially impact the outcome\n\nBiopsy control:\n\nInclusion criteria:\n\n* \\> 18 years old\n* Negative autoantibiodies and immunoglobulines\n* Referred to kidney biopsy\n\nExclusion criteria:\n\n* Lack of ability or willingness to provide informed consent\n* Significant comorbidity, which is considered to potentially impact the outcome",true,"ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","1 Year","OBSERVATIONAL","Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE) that can lead to irreversible kidney damage if not detected and managed promptly. LN is classified and treated based on its histopathological features obtained by invasive kidney biopsy. Recent research has suggested urinary extracellular vesicles (uEVs) as potential non-invasive biomarkers. The primary objective of this prospective study is to investigate the utility of uEVs in LN.",[26],"Systemic Lupus Erythematosus Nephritis",[28,29,30,31],"Systemic Lupus Erythoematosus nephritis","Lupus nephritis","complement activation","kidney biopsy","RECRUITING","2025-09-02",{"date":35,"type":36},"2025-09-09","ACTUAL",{"date":38,"type":36},"2024-11-15",{"date":40,"type":21},"2030-05-01",{"name":42,"class":43},"Kolding Sygehus","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100544824","the-role-of-proprotein-convertase-subtilisinkexin-type-9-in-kidney-damage-in-nephrotic-syndrom-100544824","NCT06373913","The Role of Proprotein-convertase-subtilisin\u002FKexin-type 9 in Kidney Damage in Nephrotic Syndrom","PCSK9","Inclusion Criteria:\n\n* 18 years old\n* Patients admitted to the Medical Department and\u002For the Medical Emergency Department, Kolding Sygehus.\n\nExclusion Criteria:\n\n* Refusal to give informed consent\n* Treatment with PCSK9 inhibitors\n* Any acute or chronic condition that would limit the ability of the patient to participate in the study\n* Control group: proteinuria",{"count":52,"type":21},75,"Nephrotic syndrome (NS) is characterized by gross proteinuria (\\>3.5 g\u002Fday), hypoalbuminaemia, edema and often hyperlipidemia. Hyperlipidemia is correlated with increased morbidity and mortality.\n\nThe study aim is to investigate the role of the protein convertase subtilisin\u002Fkexin type 9 (PCSK9) in hyperlipidemia of NS, which has been suggested to play an important role. This is done by testing the following hypotheses:\n\n1. PCSK9 is increased in patients with NS and hyperlipidemia compared to kidney-healthy controls\n2. The level of PCSK9 in plasma correlates to the degree of proteinuria.\n3. PCSK9 i increased in the kidney tissue of patients with NS\n\nThe study will compare plasma levels of PCSK9 in correlation with degree of protein in the urine between test persons with NS and kidney healthy controls. Furthermore the investigators will study the the degree of PCSK9 in the kidney in biopsies obtained from test persons with nephrotic syndrome and test persons without proteinuria.",[55,56],"Hyperlipidemias","Nephrotic Syndrome",{"date":35,"type":36},{"date":59,"type":36},"2023-06-01",{"date":61,"type":21},"2028-07-30",{"name":42,"class":43},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":63},"100564607","transverse-versus-longitudinal-groin-incision-in-vascular-surgery-100564607","NCT06631378","Transverse Versus Longitudinal Groin Incision in Vascular Surgery","The Incidence of Surgical Site Complications in Transverse Versus Longitudinal Groin Incision in Vascular Surgery: A Randomized Clinical Trial","Inclusion Criteria:\n\n• Patients undergoing vascular reconstruction with a groin incision\n\nExclusion Criteria:\n\n* Patients previously operated with a groin incision.\n* Patients undergoing operation due to trauma, bleeding, or pseudoaneurysm.\n* Patients operated within the first 24 hours of admission.\n* If it prior to the operation is deemed necessary with a muscleplasty.",{"count":72,"type":21},232,"INTERVENTIONAL",[75],"NA","The purpose of the study is to examine whether incision type has an influence on the development of groin wound complications after operation in the groin in vascular surgery.\n\nThe main questions it aims to answer are:\n\nDoes a transverse incision in the groin lead to fewer surgical site complications than a longitudinal incision? Does a transverse incision lead to fewer readmissions, fewer reoperations, shorter length of hospital stay, and a lower amputation rate.\n\nParticipants will undergo vascular surgery in the groin with either a transverse or longitudinal incision. The incision type will be selected randomly.",[78,79],"Peripheral Arterial Disease(PAD)","Aneurysmal Disease",[81,82,83,84,85,86],"groin wound complications","surgical site complications","surgical site complication","vascular surgery","incision type","incision","2025-06-24",{"date":89,"type":36},"2025-06-27",{"date":91,"type":36},"2025-03-01",{"date":93,"type":21},"2027-07-01",{"name":42,"class":43},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":73,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100406585","scandinavian-humeral-diaphyseal-fracture-trial-100406585","NCT04574336","Scandinavian Humeral Diaphyseal Fracture Trial","Scandinavian Humeral diAphyseal Fracture Trial - A Pragmatic Randomized Controlled Trial","SHAFT","1. Fracture types 12A-C (OTA\u002FAO classification)\n\n   a. Includes minimal displaced extra-articular fracture extensions to the proximal humerus (less than a 1 cm or 45 degree angulation)\n2. Treatment within 14 days from trauma\n3. Age 18-64 years for SHAFT-Y and ≥65 years for SHAFT-E\n4. Patients must understand the information given and be able to read and speak Danish, Swedish or Norwegian to complete the study paperwork\n\nAll fracture extensions involving the distal humerus and displaced fracture extensions involving the proximal humerus will not be included. Isolated fractures to the proximal or the distal end of the humerus are not eligible for screening. The proximal and distal end segments of the humerus are defined by squares of which the sides are the widest length of the epiphysis\u002Fmetaphysis in question on the anterior-posterior view.\n\nExclusion criteria\n\n1. Inability to give informed consent\n2. Undisplaced shaft fracture (less than a cortex-wide displacement in all radiographic plane)\n3. Vascular injury in ipsilateral arm\n4. Polytrauma (defined as a trauma with one or more concurrent fractures to the upper extremities or other trauma absolute indications for surgical intervention)\n5. Pathological fracture\n6. Open fracture\n7. BMI \\> 40\n8. Health conditions preventing either treatment",{"count":104,"type":21},287,[75],"This pragmatic multicenter randomized controlled trial (RCT) includes adult participants with an acute humeral shaft fracture to compare surgical fixation of humeral shaft fracture to non-surgical treatment with early identification and treatment of delayed union by a patient-reported outcome after 52 weeks. The trial population of 287 participants The trial population is divided in two age-groups due to the changes in DASH score by age. The definition of delayed union differs in the young and elderly population to consider dissimilarity in bone healing rates and the timepoint for crossover is therefor different between the groups. Participants will be randomized 1:1 between non-surgical treatment and surgical treatment. The primary outcome is the Disability of Arm, Shoulder and Hand (DASH) score at 52 weeks, and is assessor blinded. The secondary outcomes are DASH score earlier than 52 weeks, EQ-5D-5L, pain assessed by visual analogue score, Constant-Murley score including elbow range of motion and anchor-questions collected at all timepoints throughout the trial. All complications will be reported including; infection, nerve or vascular injury, surgical revisions (implant malpositioning, hardware failure, aseptic loosening and peri-implant fracture), major adverse cardiovascular events, other major adverse events and mortality. SHAFT will provide information on the effectiveness of two standard treatments for humeral shaft fractures, while taking the dilemmas within the population into account.",[108],"Fracture Humerus of Shaft",[110,111,112,113,114,115,116],"Humeral shaft fracture","Diaphysis","Fracture fixation","Fracture Healing","Aged","Randomized Controlled Trial","Comparative study","2024-04-15",{"date":119,"type":36},"2024-04-16",{"date":121,"type":36},"2022-04-04",{"date":123,"type":21},"2031-07-31",{"name":42,"class":43},22,""]